Showing papers by "Vahakn B. Shahinian published in 2013"
TL;DR: Estimation of CKD prevalence within health care systems is feasible, but discrepancies between observed and predicted prevalences suggest that this approach is dependent on data availability and quality of information for comorbid conditions, as well as the frequency of testing for CKD in the health care system.
34 citations
TL;DR: There has been a sharp increase in rates of BMD testing among men receiving ADT for prostate cancer over time, beyond rates noted in contemporaneous controls, and in men who have a PCP involved in their care.
Abstract: BACKGROUND
Practice guidelines recommend bone mineral density (BMD) monitoring for men on androgen deprivation therapy (ADT) for prostate cancer, but single center studies suggest this is underutilized.
19 citations
TL;DR: Increased technology penetration is associated with a slightly higher rate of prostate specific antigen testing and no change in the prostate biopsy rate, temper concerns that adopting new technology accelerates diagnostic testing for prostate cancer.
13 citations
TL;DR: The challenge of optimizing androgen deprivation therapy (ADT) for prostate cancer has been illustrated by two recent papers which showed that practice patterns of ADT are not always in line with recommended guidelines.
Abstract: The challenge of optimizing androgen deprivation therapy (ADT) for prostate cancer has been illustrated by two recent papers. A preclinical study demonstrated that the effects of androgen deprivation on prostatic neoplastic tissue are not necessarily beneficial and a large database analysis showed that practice patterns of ADT are not always in line with recommended guidelines.
1 citations